source
- Merck and Daiichi withdraw lung cancer ADC filing after FDA says data insufficientMerck and Daiichi Sankyo have pulled their application for accelerated approval of a B7-H3-directed antibody-drug conjugate aimed at extensive-stage small cell lung cancer. The FDA indicated that…
- Regenerative medicine requires diagnostics and product characterization beyond stem cell basicsStem cell therapies are often portrayed as a single treatment, but they actually vary widely in tissue source, cell passage, viability and delivery methods. Experts say a credible regenerative app…